E.g., 14-04-2021
E.g., 14-04-2021
We have found 68 results.
View by: Grid List
Sort by: Relevancy Date
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: The Case For Ex-US Equities

    The US trade deficit cycle suggests the world is heading towards a protracted period of US dollar depreciation. With valuations outside the US relatively attractive, and deglobalization meaning ex-US equities will offer greater diversification benefits in future, investors should consider increasing their exposure to ex-US equities.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: The Threat Of Rising Inflation And Yields

    The roll-out of vaccines in the US is upending the investment environment, as the focus shifts beyond the pandemic to full-throttled economic recovery. With both monetary and fiscal policy set to remain loose, nominal growth could soon rip. Hopes for “normalization” have driven up inflation expectations and freaked out bond investors. Those getting fixed interest are right to be unnerved, as production capacity is fairly tight, inventories are...

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Europe’s Troubled Trajectory

    For the eurozone, it seems everything went wrong at the end of 2020—and things have only got worse at the beginning of 2021. Unfortunately, hopes for recovery are pinned on a vaccination program which has been late to start, slow to gather speed, and beset by problems. Nevertheless, despite this gloomy prognosis, there will still be opportunities for investors.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Darkness Before Dawn? The Covid Vaccine Outlook

    As a new wave of Covid infections grips major economies, and social restrictions return, the hopes for a return to pre-pandemic normal rest on the rollout of vaccines. With vaccine production ramping up, most developed economies could reach herd immunity by late in 2021. But many emerging economies will take longer, and several risk factors could still derail the rollout.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Two Equity Rotations For A Post-Covid World

    The impending rollout of vaccines in the United States is spurring two big equity rotations. With investors looking ahead to a post-Covid world, a rotation has begun from stocks that thrived in the pandemic to those that merely clung on. Second, the expectation that a robust economic recovery will push interest rates up has caused beaten-down value stocks to recover some mojo. Investors should play these rotations at a granular, sub-sector level...

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Chinese Assets After The Recovery

    China was the first economy into lockdown, and the first to emerge, enjoying a rapid rebound in industrial production and exports. Uniquely among major economies, China has already regained and exceeded pre-Covid levels of output. The speed and strength of this early recovery was reflected in financial markets, with equities rallying hard, bonds selling off, and the renminbi appreciating on heightened capital inflows.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: The Real US Election Risks

    Some investors worry that a contested US election may spark social and political unrest that is serious enough to threaten US risk assets. They are likely focused on the wrong risk. The US’s democracy faces heavy strains but is nowhere near a breaking point, but the differing outcomes that can occur on (or after) November 3 pose threats to portfolios.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Eight Questions, 11 Answers

    With US equities once again at record highs and the Fed promising to keep rates nailed to the floor, it is time to ask hard questions of the bull market that won’t die. That interrogation is conducted by Charles and Louis Gave. In these strange times, the case for owning anti-fragile assets has rarely been stronger, they contend. Four stand out for having weathered the pandemic and should be treated seriously.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: From Bullish To Neutral On The US

    The upsurge in second-round Covid-19 infections has put the US economic recovery on hold for now. But government, businesses and consumers have got better at coping with Covid, and in contrast to the first round, the economy is not going backwards.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: A New European Dawn?

    European nations have managed to lay the ground for a putative fiscal union. In a change of tack, Germany has changed tack by embracing demand management policies. Its new approach should drive a more balanced and domestically-focused recovery that may lift the eurozone-wide return on invested capital. Nick and Cedric argue that this changed dynamic is likely to attract foreign capital and lift the euro against the US dollar.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Recovery And Its Risks

    As economies have begun to emerge from their coronavirus lockdowns, there remain two big near-term macro risks that could derail a recovery. On one hand, solid demand on top of massive central bank monetary expansion could fuel rising inflation. On the other, a big round of permanent job losses could dent demand and slow the economic recovery.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Emerging Markets Under Pressure

    Aside from China, emerging markets have not been hit as hard as rich countries by Covid-19, but their asset markets have been hammered. An optimistic view holds that undervalued EM assets can now bounce back. Udith and Vincent are more cautious: a dollar-squeeze could yet hurt markets that have otherwise decent fundamentals and attractive valuations.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Lockdowns And Lost Output

    Markets have been upended by the twin uncertainty of Covid-19’s rapacious spread and the economic effects of stopping it. Massive policy responses have convinced investors that a V-shaped recovery is possible, but this is far from certain. As the outbreak in Europe and the US hits its peak phase over the next month, markets will swing on the timing of any proposed exit from lockdowns.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Global Virus, Local Reactions

    In the last week of February, global investors woke up to the massive effect of China’s coronavirus lockdown and the risks of a global pandemic. The resulting disruption to global supply chains will be widespread and long lasting. But not all is bleak. The Fed has promised to support the US economy, and many emerging markets have room both for expansionary fiscal policies and interest rate cuts.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Covid-19 And Emerging Markets

    The rapid spread of Covid-19 has spooked investors and triggered steep sell-offs in Chinese and Asian markets. But there are good reasons to hope the spread of the disease will be contained in the coming weeks, at which point Chinese and regional equities can recover.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: China's Balancing Act Gets Easier

    In 2019, investors were cowed by the US-China trade war and Chinese policymakers’ efforts to balance growth and financial stability. This year, these factors will weigh less heavily: the US and China are set to ink a trade deal, while China is shifting more toward growth-supporting policies. Such a combination is mildly bullish for both Chinese bonds and equities.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Risk Assets In 2020

    World stock markets have enjoyed a solid couple of months as geopolitical risks have abated and the manufacturing slowdown appears to have leveled off. With major central banks all printing money simultaneously for the first time since the financial crisis, and fiscal policy easing at the same time, there are good reasons to believe the rally will be sustained into 2020.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: Towards A Dollar Decline

    The last five years have been an era of US dollar strength. That era may now be coming to an end. After the US Federal Reserve halted its balance sheet contraction and last month resumed buying T-bills at a rate of US$60bn a month, the Fed is now printing money faster than the other central banks. As a result, relative liquidity growth now favors US dollar weakness.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: An Asian Repricing

    Asian inflation has decoupled from other emerging market regions and may be settling at a new permanently lower level. At the same time, lower Asian inflation also reflects weak capital spending and slower economic growth due to the global trade downturn. The best way to play this new low-inflation, low-growth era is with regional bonds.

    0
  • Please login, request a trial or contact our sales team for more information

    Gavekal Research

    Strategy Monthly: The Message From Bonds

    Record low bond yields point to a deflationary catastrophe in the making. Yet growth data in the world’s two biggest economies remain decent. Could investors be reacting to a rupture in the international order? Gavekal analysts are not persuaded by such arguments and offer four alternative explanations for the “bond bubble”.

    0
Show me: results